AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Envelaf 75mg Capsule XR

Prescription Icon
Prescription Required

Marketer

Alkem Laboratories Ltd

Salt Composition

Venlafaxine (75mg)

Overview Envelaf 75mg Capsule XR

Axilon 75mg Extended-Release Capsules treat depression and anxiety. This medication modifies brain chemistry, alleviating anxiety symptoms like agitation, edginess, poor concentration, tiredness, perspiration, rapid heartbeat, and racing thoughts. Take Axilon 75mg XR with food, consistently at the same time daily for stable blood levels. If a dose is missed, take it immediately upon recall. Complete the prescribed course, even with improvement; abrupt cessation can exacerbate symptoms. Common side effects include queasiness, vomiting, sleep disturbances, reduced appetite, heightened anxiety, constipation, increased sweating, and sexual difficulties. Dizziness and drowsiness may occur; avoid driving or tasks requiring alertness until effects are known. These side effects are typically transient. Persistent or bothersome effects warrant medical attention. Before starting Axilon 75mg XR, disclose any kidney, heart, liver issues, or seizure history. Report any unusual mood or behavioral shifts, worsening depression, or suicidal ideation to your physician.

Uses of Envelaf 75mg Capsule XR

Mood disorders encompassing depressive and anxious symptoms

Major Benefits of Envelaf 75mg Capsule XR:

Consume this medication according to your physician's prescribed dosage and schedule. Ingest the 75mg Envelaf XR capsule whole; avoid chewing, crushing, or fracturing it. Administer this medication with a meal.

Common Side effects of Envelaf 75mg Capsule XR:

  • Nausea
  • Vomiting
  • Dizziness
  • Insomnia (difficulty in sleeping)
  • Decreased appetite
  • Anxiety
  • Constipation
  • Increased sweating
  • Sexual dysfunction

How to use Envelaf 75mg Capsule XR:

Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and duration. Ingest the entire capsule; avoid chewing, crushing, or breaking it. The Envelaf 75mg extended-release capsule should be taken with a meal.

How Envelaf 75mg Capsule XR works:

Envelaf 75mg extended-release capsules elevate brain levels of serotonin and norepinephrine, neurotransmitters crucial for emotional equilibrium.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Combining Envelaf 75mg Capsule XR and alcohol is unsafe.

PregnancyPregnancyCONSULT YOUR DOCTOR

The extended-release Envelaf 75mg capsule may pose risks during pregnancy. While human data is scarce, animal research indicates potential harm to a developing fetus. A physician will assess the advantages against possible risks prior to prescribing. Seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Extended-release Envelaf 75mg capsules are likely unsafe for breastfeeding mothers. Available human data indicate potential drug transfer to breast milk, posing a risk to the infant. Infants should be observed for drowsiness and monitored to ensure appropriate weight increase.

DrivingDrivingUNSAFE

Driving ability may be impaired by Envelaf 75mg XR capsules, due to potential side effects including dizziness, confusion, and visual disturbances like blurred vision.

KidneyKidneyCAUTION

Extended-release Envelaf 75mg capsules require careful administration for individuals with impaired kidney function. Dosage modification of Envelaf 75mg extended-release capsules might be necessary. Physician consultation is advised.

LiverLiverCAUTION

Extended-release Envelaf 75mg capsules require careful administration for individuals with hepatic impairment. Dosage modification of Envelaf 75mg extended-release capsules may be necessary. Physician consultation is advised.

What if you forget to take Envelaf 75mg Capsule XR :

Should you forget to take your Envelaf 75mg Capsule XR, administer it immediately upon remembrance. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing pattern. Avoid taking a double dose.

Facts to Know About Envelaf 75mg Capsule XR

LabelValue
Type of Compound Methoxybenzene compound
Addictive None.
Treatment Category Central and Peripheral Nervous System
Mechanism of Action Drugs that block the reabsorption of serotonin and norepinephrine

FAQs on Envelaf 75mg Capsule XR

Confirmed. Envelaf 75mg extended-release capsules may induce drowsiness. Disclose current use of other sleep aids to your physician prior to commencing Envelaf 75mg extended-release capsules.
Affirmative. Envelaf 75mg extended-release capsules are classified as a psychotropic medication. Psychotropic medications are defined as any drugs influencing mental processes, feelings, and actions.
Envelaf 75mg extended-release capsules are not classified as narcotics. Narcotics are opioid-derived substances, such as heroin and morphine, known for their sedative effects.
These are identical medications. Envelaf 75mg capsules, whether labeled XR or ER, are extended-release formulations, delivering the drug gradually for sustained therapeutic levels. Extended-release preparations offer the benefit of reduced dosing frequency.
Mirtazapine and Envelaf 75mg XR capsules should not be taken together. Concurrent use poses a significant risk of serotonin syndrome, a potentially fatal condition. Symptoms may include agitation, hallucinations, nausea, vomiting, diarrhea, rapid heart rate, fluctuating blood pressure, fever, and coma.
Concurrent use of citalopram and Envelaf 75mg XR capsules, both serotonin-boosting medications, is contraindicated. A substitute medication should be considered to prevent serotonin syndrome, a potentially fatal condition characterized by agitation, hallucinations, gastrointestinal distress (nausea, vomiting, diarrhea), rapid heart rate, fluctuating blood pressure, fever, and potentially coma.
Envelaf 75mg Capsule XR is effluxed from the brain by P-glycoprotein. Research indicates that Envelaf 75mg Capsule XR and its byproduct suppress P-glycoprotein activity.
Extended-release Envelaf 75mg capsules are absorbed in the intestinal tract following hepatic metabolism.
Extended-release Envelaf 75mg capsules are prescribed for major depressive disorder. Physician consultation is required prior to use.
Treatment with Envelaf 75mg extended-release capsules may cause a persistent rise in blood pressure for some individuals. Regular blood pressure checks are advised for patients using Envelaf 75mg extended-release capsules. A lower dosage or treatment cessation may be necessary for these patients.
Confirmed. Envelaf 75mg extended-release capsules can induce constipation in certain individuals. Increasing dietary fiber intake and fluid consumption is recommended. Laxative use may also be considered. Your physician can provide guidance on prevention and management. Seek medical attention if constipation persists or worsens.
Confirmed. Some individuals taking Envelaf 75mg extended-release capsules experience weight reduction. Clinical trials demonstrated a correlation between dosage and weight loss in patients using this medication for an extended period. Seek medical advice if this side effect is concerning.
Envelaf 75mg extended-release capsules are not considered habit-forming.
A tablet may be substituted for the capsule, however, this should only occur with a physician's guidance and authorization. Self-initiated changes are inadvisable, as varying drug formulations affect medication release and consequently, treatment efficacy. This alteration could result in suboptimal therapy, adverse reactions, or treatment failure.
Concurrent use of gabapentin and Envelaf 75mg XR capsules is possible, but necessitates prior medical consultation. Combined administration may heighten drowsiness, somnolence, and impair concentration. Proceed with caution.
Desvenlafaxine, the active component of Envelaf 75mg XR capsules, is the drug in its pharmacologically active state.
Extended-release Envelaf 75mg capsules lack regulatory approval for fibromyalgia treatment. Preliminary research suggests potential benefits, however. Physician consultation is recommended prior to initiating this medication.
Extended-release Envelaf 75mg capsules lack regulatory approval for treating neuropathic pain; however, studies suggest its effectiveness in managing this condition. Consequently, it's employed off-label for nerve pain relief.
Extended-release Envelaf 75mg capsules are associated with alterations in brain neurochemistry, resulting in reduced appetite. This appetite suppression is correlated with the administered dose.
Should you experience reduced libido or erectile dysfunction, consult your physician to explore alternative treatment options. Do not discontinue Envelaf 75mg Capsule XR independently; doing so may worsen side effects.
Envelaf 75mg Capsule XR
32
MRP 39
17% off